Ongoing

• OPPURE: Intensified AAV purification network.
  2021-2024, PTDC/EQU-EQU/0142/2020
• AAVScreen: Overcoming the challenges of recombinant adenoassociated virus production to treat Muscular dystrophy.
  2021-2024, PTDC/BTM-ORG/1383/2020
• AstroReact:Unraveling the role of astrocyte-induced neural microenvironment remodeling in traumatic brain injury pathobiology.
  2018-2021, AVISO 02/SAICT/2017
• ESSENCE: A função das células senescentes induzidas na regeneração da medula espinal.
  2018-2021,PTDC/MED-NEU/30428/2017
• Muvha: Vacina multivalente inactiva contra pericardite exsudativa dos ruminantes em Africa.
  2018-2021, LEAPAgri/001/2017
• ACCELENTI: Aceleração da produção de Lentivirus através da engenharia.
  2018-2021, AVISO 02/SAICT/2017
• LIVES: Live cell sensors for virus detection: enabling drug and vaccine development for neglected diseases.
  2018-2021, AVISO 02/SAICT/2017
• MetaCardio: Metabolic signatures of human pluripotent stem cells derived cardiomyocytes for improved cell therapy.
  2018-2021, AVISO 02/SAICT/2017
• ReaViVe: Surface enhanced Raman detection of adeno associated virus vectors for production optimization.
  2018-2021, AVISO 02/SAICT/2017
• FIGHT-TWO: Edible bait vaccine for rabbit haemorrhagic disease virus 2 (RHDV2) control in wild rabbits.
  2018-2021, AVISO 02/SAICT/2017
• NeoCoronary: Role of CCBE1 during coronary vasculature development and neo-angiogenesis upon myocardial infarction through stimulation of VEGF-C signaling.
  2018-2021, AVISO 02/SAICT/2017
• PEFPlateletValue: Pulsed Electric Fields for valorization of platelets with no therapeutic value into a high biomedical potential product.
  2018-2021, AVISO 02/SAICT/2017
• FINNEE: From spectra to formulas.
  2018-2021, AVISO 02/SAICT/2017

Concluded

• ERAdicatPH: Understanding primary hyperoxaluria type 1 towards the development of innovative therapeutic strategies.
  2016-2019, E-Rare3/0002/2015, funded by FCT, Portugal
• Therapeutic Targets for Triple Negative Breast Cancer: Development of mono and bispecific antibodies against Notch1 ligands.
  2016-2019, PTDC/BBB-BMD/4497/2014, funded by FCT, Portugal
• NETDIAMOND: New targets in diastolic heart failure: from comorbidities to personalized medicine.
  2016-2019, POCI-01-0145-FEDER-016385
• CardioRegen: Integrative studies from the embryo to Scalable Multipronged Generation of hESC-derived Myocardial progenitors for heart repair.
  2015-2019, HMSP-ICT/0039/2013, HMS program, funded by FCT, Portugal
• Engineering biosensors for human cell type and state diagnosis using synthetic digital computation.
  2018-2019, MIT-EXPL/BIO/0097/2017
• Establishment of a flexible insect cell platform for fast production of pseudo-typed VLPs for drug and vaccine development.
  2014-2015, EXPL/BBB-BIO/1541/2013, funded by FCT, Portugal
• Molecular approaches to develop an insect cell production system for Hepatitis C vaccine candidate.
  2014-2015, EXPL/BBB-BIO/1129/2013, funded by FCT, Portugal
• Development of a scalable strategy for stem cells purification.
  2013-2014, EXPL/BBB-EBI/1003/2012, funded by FCT, Portugal.
• Systems biotechnology for improved production of biopharmaceuticals in animal cells.
  2013-2015, PTDC/BBB-BSS/0518/2012, funded by FCT, Portugal.
• Combining siRNA and AAV therapy approaches to target human basal-like breast cancer: from vector development to anti-tumor efficacy evaluation.
  2013-2015, PTDC/BBB-BIO/1240/2012, funded by FCT, Portugal.
• Integrative approaches to depict human cardiac stem cell receptome and its role in the cardiac regenerative process.
  2013-2015, PTDC/BBB-BIO/1414/2012, funded by FCT, Portugal.
• A novel generation of packaging cell lines for the manufacture of lentivirus based biopharmaceuticals.
  2012-2015, PTDC/EBB-BIO/118615/2010, funded by FCT, Portugal.
• Development of improved suspension MDCK cell lines for the production of viral based bioproducts: manufacturing Influenza and Adenovirus.
  2012-2015, PTDC/EBB-EBI/118621/2010, funded by FCT, Portugal.
• Human central nervous system in vitro models for preclinical research: new tools for studying viral vector-mediated gene.
  2012-2015, PTDC/EBB-BIO/119243/2010, funded by FCT, Portugal.
• Probing adenovirus-host cell interactions: a systems biotechnology approach to improve production of gene delivery vectors.
  2012-2015, PTDC/EBB-BIO/119501/2010, funded by FCT, Portugal.
• Development of function blocking antibodies using Phage Display Technology: Inhibiton of the Notch1 signaling pathway by function blocking anti-jagged 1 antibody.
  2012-2016, PTDC/SAU-ONC/121670/2010, funded by FCT, Portugal
• MSVida: The architecture of life - Probing the quaternary structure of virus capsids by native mass spectrometry.
  2012-2016, RECI/BBB-BEP/0104/2012, funded by FCT, Portugal
• 3D in vitro models for reducing animal experimentation in pharmaceutical development: integrative approaches for prediction of hepatic drug metabolism and neurotoxicity.
  2011-2014, PTDC/EBB-BIO/112786/2009, funded by FCT, Portugal.
• Preconditioning triggered by Carbon monoxide: new strategies to prevent brain damage due to hypoxia-ischemia and reperfusion.
  2010-2012, PTDC/SAU-NEU/098747/2008, funded by FCT, Portugal.
• 2D fluorometry: a powerful tool to improve mammalian cell process development.
  2010-2012, PTDC/EBB-EBI/102750/2008, funded by FCT, Portugal.
• Novel Cell Factories for the production of secreted complex bioproducts: a syntetic biology approach for improved product Stoichiometries.
  2010-2012, PTDC/EBB-EBI/102266/2008, funded by FCT, Portugal.
• BACULOME-Engineering cellular energetics for improvement of bioprocesses: metabolic modeling for enhanced vaccines production.
  2010-2012, PTDC/EBB-EBI/103359/2008, funded by FCT, Portugal.
• Retroviral like particles: improving potential as candidate vaccines for Hepatitis C.
  2010-2012, PTDC/EBB-BIO/102649/2008, funded by FCT, Portugal.
• Using functional genomics to improve mammalian cells for virus based biopharmaceuticals manufacture.
  2010-2012, PTDC/EBB-BIO/100491/2008, funded by FCT, Portugal.
• Integrated strategies for expansion, neuronal differentiation and cryopreservation of human embryonic stem cells.
  2009-2012, funded by FCT (PTDC/BIO/72755/2006)
• Fundamentals of downstream processing of enveloped viruses: towards an integration of purification processes.
  2007-2010, funded by FCT (PTDC/EQU-EQU/71645/2006)
• Manufacturing canine adenovirus vectors for gene therapy: development of MDCK CAV-2E1- transcomplementing cell lines.
  2007-2010, funded by FCT (PTDC/BIO/69452/2006)
• Development of flexible cell lines for the Production of Retrovirus and Lentivirus for Gene Therapy.
  2007-2010, funded by FCT (PTDC/BIO/69451/2006)
• Novel stroke model for neuroprotective research: bioreaction of primary brain cell aggregates.
  2007-2010, funded by FCT (PTDC/BIO/69407/2006)
• Carbon monoxide as a neuroprotective agent against hypoxia-ischemia and reperfusion.
  2007-2010, funded by FCT, Portugal (PTDC/SAU-NEU/64327/2006)
• Advanced Control of BHK Cultivation Processes Based on Intracellular Metabolic Fluxes.
  2005-2007, funded by FCT, Portugal (POCI/BIO/57927/2004)
• THERAVECT - Production, Purification and Storage of Retroviral Vectors Produced by Modular Master Producer Cells.
  2005-2007, funded by FCT, Portugal (010.6/A003/2005)
• CELL CRYOTHERA - Cell Cryopreservation for Therapy and Regenerative Medicine.
  2005-2007, funded by FCT, Portugal (010.6/A006/2005)
• Genetics, Stoicheometry and Kinetics of Multiple Protein Assembly: the case for a Rotavirus Like Particle.
  2005-2007, funded by FCT (POCTI/BIO/55975/2004)
• Integrated strategy for the production, purification and storage of adenovirus.
  2004-2006, funded by FCT, Portugal (POCTI/BIO/46515/2002)
• Metabolic Trafficking between neurons and astrocytes under stress conditions implicated in neurological disorders.
  2003-2006, funded by FCT, Portugal (POCTI/BIO/39214/2001)
• Stabilization of retroviruses for gene therapy clinical applications.
  2001-2003, funded by FCT, Portugal (POCTI/BIO/35695/2000)
• Cell cycle control for better biotechnological methods in therapeutic protein production.
  2001-2003, funded by FCT, Portugal (POCTI/BIO/35687/2000)